Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Symptoms and General Pathology

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

Behaviors and Mental Disorders

Rare Diseases

Breast Neoplasms

Prostatic Neoplasms

Neoplasm Metastasis

Multiple Myeloma

Neoplasms, Plasma Cell

Pain

Breast Diseases

Skin Diseases

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Quality of Life

Bone Density Conservation Agents

All Drugs and Chemicals

Zoledronic Acid

zoledronic acid

Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.

Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions

A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions

Novartis

case group = patients with multiple myeloma

monoclonal gammopathy of undetermined significance

blood samples

Bone marow samples

Valéry SALLE, PhD

The Primary objective of this study is to compare serum levels of Macrophage-Colony Stimulating Factor (M-CSF) in a population of patients with multiple myeloma (MM), in a population of patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and in a control population.

Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma

determined by the presence of osteolytic lesions, osteopenia or pathological fractures, presence of bone pain

Centre Hospitalier Universitaire, Amiens

Zoledronic acid

To evaluate the safety and tolerability of intravenous zoledronic acid in the treatment of patients with multiple myeloma stage III with bone lesions related to Cancer.

Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions	NCT00029224	Breast Cancer Multiple Myelom... Prostate Cancer	zoledronic acid	18 Years -	Novartis
Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma	NCT02800954	Multiple Myelom...	blood samples Bone marow samp...	18 Years - 99 Years	Centre Hospitalier Universitaire, Amiens
Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma	NCT02800954	Multiple Myelom...	blood samples Bone marow samp...	18 Years - 99 Years	Centre Hospitalier Universitaire, Amiens
Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.	NCT00242528	Multiple Myelom...	Zoledronic acid	18 Years - 80 Years	Novartis

Spots Global Cancer Trial Database for bone lesions

Every month we try and update this database with for bone lesions cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.